跳至主要内容
临床试验/NCT05480215
NCT05480215已完成不适用

Prospective Study for Symptomatic Relief of Action Tremor With Cala Trio Using Trio+ Bands

Cala Health, Inc.2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2021年10月7日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
20
试验地点
2
主要终点
Tremor power changes from pre-stimulation to post-stimulation

研究概览

简要总结

Demonstrate safety and effectiveness of symptomatic action tremor relief in the treated hand following stimulation with the Cala Trio System using the Trio+ bands as compared to the Trio bands in adults with Essential Tremor (ET) and/or Parkinson's Disease (PD) over 2 weeks.

详细描述

20 patients with (13 with ET and 7 with PD) with at least mild postural tremor were enrolled in a prospective, single-center, two-arm, crossover study that took place over the course of four weeks. TAPS devices were shipped to patients to run the study remotely. In the first arm of the study, subjects received TAPS treatment using the original. Cala Trio band for two weeks. Followed by a wash-out period (> 24 hours), subjects entered the second arm and received TAPS using the Trio+ band for an additional two weeks. Unsupervised motion assessments were captured at home, and at the beginning and end of the four weeks by telemedicine.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Must be ≥22 years of age
  • Competent and willing to provide written, informed consent to participate in the study
  • Willing to comply with study protocol requirements
  • For subjects with Essential Tremor:
  • A diagnosis of essential tremor
  • A tremor severity score of 2 or above in the dominant hand/arm as measured by one of the TETRAS upper limb postural tremor items
  • No significant alcohol intake within 8 hours prior to study visits
  • For subjects with Parkinson's Disease:
  • Dominant hand/arm exhibiting postural tremor ≥ 2 (while in the off state) as assessed by the MDS-UPDRS postural tremor score
  • Stable dose of Parkinson's disease medications, if applicable, for 30 days prior to study entry

排除标准

  • Implanted electrical medical device, such as a pacemaker, defibrillator, or deep brain stimulator
  • Suspected or diagnosed epilepsy or other seizure disorder
  • Any skin condition at the stimulation site that in the investigator's opinion should preclude participation in this study
  • Diagnosed with peripheral neuropathy affecting the tested upper extremity
  • Presence of any other neurodegenerative disease other than essential tremor or Parkinson's Disease
  • Subjects unable to communicate with the investigator and staff
  • Any health condition or concomitant medication that in the investigator's opinion should preclude participation in this study
  • Pregnancy or anticipated pregnancy during the course of the study
  • Botulinum toxin injection for hand tremor within 6 months prior to study enrollment
  • Are participating or have participated in another interventional clinical trial in the last 30 days which may confound the results of this study, unless approved by the Sponsor

结局指标

主要结局

Tremor power changes from pre-stimulation to post-stimulation

时间窗: baseline, pre-intervention and immediately after the intervention

Tremor improvement was measured by Tremor Power Improvement Ratio (TPIR) using kinematic data collected by the device. The TPIR was calculated as pre-stimulation power divided by post-stimulation power, which was computed from device-collected accelerometer data

次要结局

  • Change in BF-ADL(baseline, pre-intervention and immediately after the intervention)
  • Change in UPDRS Part III from pre-stimulation to post- stimulation within each visit(baseline, pre-intervention and immediately after the intervention)
  • Change in TETRAS from pre-stimulation to post- stimulation within each visit(baseline, pre-intervention and immediately after the intervention)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验